These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Long-term follow-up of patients with Roux-en-Y gastrojejunostomy for gastric disease. Author: McAlhany JC, Hanover TM, Taylor SM, Sticca RP, Ashmore JD. Journal: Ann Surg; 1994 May; 219(5):451-5; discussion 455-7. PubMed ID: 8185395. Abstract: OBJECTIVE: A consecutive series of Roux-en-Y gastrojejunostomies with a mean follow-up of 11.9 years was reviewed to characterize the long-term results of patients having this operation to treat or prevent bile reflux gastritis. SUMMARY BACKGROUND: Development of postprandial abdominal discomfort, nausea, vomiting, or bezoar formation (Roux stasis syndrome) in the postoperative follow-up period has prompted questions about the role of Roux-en-Y gastrojejunostomy to treat or prevent bile reflux gastritis. METHODS: Long-term clinical follow-up (mean, 11.9 years) data for 24 patients was collected by reviewing medical records, interviewing patients directly through telephone contact, or both. All patients who had symptoms in the follow-up period were evaluated by upper gastrointestinal series, endoscopy, or both. A modified Visick scale was used for clinical ratings. RESULTS: Of the 22 evaluable patients, follow-up was complete in 20; the clinical condition that prompted surgery was corrected in 21 (95%). Roux-en-Y gastrojejunostomy was successful for treating or preventing bile reflux gastritis in all 22 patients. Despite this success, clinical failure (Visick scale III or IV) was documented in 8 patients (36%). Seven of the 8 patients had clinical failure within 6 months of operation, with the Roux stasis syndrome developing in 6 of them (27%). CONCLUSION: This consecutive series of Roux-en-Y gastrojejunostomies performed by one surgeon has the longest follow-up to date. Although the Roux-en-Y gastrojejunostomy is safe and often successful, the procedure appears to be limited by a substantial rate of clinical dissatisfaction. Surgeons should be cautious in using it to treat primary or remedial gastrointestinal disease.[Abstract] [Full Text] [Related] [New Search]